Vor Bio (VOR) - Price to Earnings Ratio

The primary threats to Vor Biopharma Inc. (VOR) involve the high cost of developing personalized drugs and potential complications during testing. The business relies on unique stem cell modification methods protected by strict patent restrictions. This price chart with the 0.90 indicator confirms the company's status as an authoritative innovator in oncology therapy that commands the unconditional trust of major investors.

VOR - Vor Bio Price to Earnings Ratio over the range 07/04/2022 - 11/12/2026

Comprehensive metric breakdowns and analytics for Vor Bio (VOR)

- share price and expert price forecast:

Price Performance Chart vorbio.com|VOR - Analyst Consensus Forecast

- market capitalization indicators:

Market Value Vor Biopharma Inc.|VOR - Total Company Value

- book capitalization information:

Net Assets per Single Share Vor Biopharma|VOR - Company Book Value|Market-to-Book Ratio vorbio.com|VOR - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market ratios statistics:

VOR - Net Income|Expected Net Income Vor Biopharma Inc.|VOR - P/E Multiple|Future Price to Earnings Vor Biopharma, Inc.|VOR - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Vor Biopharma Inc.|VOR - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Vor Biopharma|VOR - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months vorbio.com|VOR - Earnings growth in current year|Expected earnings per share trend next year Vor Biopharma Inc.

General company analysis:vorbio.com

Defensive portfolio screening requires an accurate valuation of a business relative to its earnings. This ratio measures invested capital density by correlating the market price of a share to the net income per share. For Vor Biopharma Inc. (VOR), the high cost of cell therapy development makes this indicator sensitive to any clinical risks. The company's P/E ratio based on net income on GURU.Markets reflects the current level of market optimism.

Analysis of competing companies